September 12th, 2018
LEO Pharma UK/Ireland, the leading medical dermatology company, has appointed Tim Walker as Business Insights Manager for its North Europe ‘cluster’ countries
Tim brings with him over 20 years’ experience from a variety of Business Intelligence and analytical roles. Most recently Tim was Senior Business Analytics Manager at Janssen where he worked in the therapy areas of Infectious Diseases, Oncology and Psychiatry. He had responsibility for Business planning and forecasting; Dashboard development; Sales Force Effectiveness (SFE); Product launch KPI reporting and had operating company responsibility for Multichannel Analytics.
“I am thrilled to welcome Tim as Business Insights Manager to lead our Business Insights operations in Cluster Europe North, which comprises of the UK and Ireland; Nordics; Australia and New Zealand. I am confident that his leadership, extensive analytical and business knowledge together with his pharmaceutical expertise, gained across several different therapy areas will prove to be invaluable to our organisation and help us in our quest to deliver improved outcomes to patients”, said Barbara Reilly, Commercial Excellence Director, Cluster Europe North AU/NZ .
Commenting on the reasons why he joined LEO Pharma, Tim Walker explained, “I am delighted to be joining LEO Pharma at this exciting time: Their values of customer focus, innovation and adaptability have great synergy with my vision of how a high performing Business Insights team should work. The role presents a development opportunity to broaden my therapy area expertise in dermatology and widen my experience working in new territories as a result of LEO Pharma’s unique cluster structure. I relish the opportunity as I am passionate about fully integrating Business Intelligence into the wider business by providing actionable insights on company performance at all levels to help shape strategic thinking and tactical programmes. This insights led approach will be key to supporting LEO Pharma in their growth journey in shaping medical dermatology as highlighted in their new strategy towards 2025 where they are building on their entry into biologics and plan to enter rare diseases.”